Distal protection with a filter device during coronary stenting in patients with stable and unstable angina

Annalisa Angelini1, Paolo Rubartelli, Flavio Mistrorigo

  • 1Department of Pathology, University of Padua Medical School, Via A. Gabelli, 61, 35121 Padua, Italy.

Circulation
|July 28, 2004
PubMed

Insights

Filter protection during percutaneous coronary intervention (PCI) effectively captures embolic debris. Unstable angina and older age predict larger particle size, supporting device use in high-risk patients.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Distal embolization is a risk during percutaneous coronary intervention (PCI).
  • Filter protection devices are available to mitigate this risk.
  • Understanding embolic debris characteristics is crucial for optimizing PCI outcomes.

Purpose of the Study:

  • To evaluate microembolization during stent implantation in native coronary arteries.
  • To assess the quantity and characteristics of debris captured by the Angioguard filter.
  • To identify clinical and angiographic predictors of embolic particle size.

Main Methods:

  • 39 patients with coronary artery lesions underwent elective stenting with a protective filter.
  • Debris collected by the filter was analyzed for size and characteristics.
  • Clinical and angiographic data were correlated with pathological findings.

Main Results:

  • Debris was present in 75.6% of filters, with particle sizes ranging from 47 to 2503 micrometers.
  • Particles larger than 300 micrometers were found in 85.7% of filters with debris.
  • Unstable angina and age >67 years were independent predictors of larger embolic particle size (P<0.05).

Conclusions:

  • Filter protection devices can limit embolization during PCI.
  • These devices are particularly beneficial in high-risk patients, including those with unstable angina or older age.
  • Reducing embolic events may improve patient outcomes after PCI.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...